Seller record · Telehealth service

Maximus

By Peptide Alliance, Editorial publisherRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S3, pharmacy identification: The about page heads a section on selecting pharmacy partners and names none. The terms, privacy, contact and treatment surfaces add no facility. 1 more criterion also fails; see the table below.

At a glance

MaximusTelehealth service

6/8criteria passed

Price: From $149.99
Sells: compounded semaglutide, compounded tirzepatide, Wegovy, and 4 more
FDA letters: 1 on file

Visit Maximus See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A performance-medicine telehealth service selling compounded semaglutide and tirzepatide beside brand GLP-1 pens and tablets. It states that it runs its own clinical studies and publishes the results.

Operating entity Maximus Health, Inc.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Maximus' about page
S2	Prescription gating	PASS	Maximus' weight loss start page on its app site
S3	Pharmacy identification	FAIL	Maximus' about page
S4	Compounding disclosure	PASS	Maximus' semaglutide standard page
S5	Analytical documentation	FAIL	Maximus' weight loss page
S6	Business address	PASS	Maximus' terms of use page
S7	Price disclosure	PASS	Maximus' website
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSThe about page states that board-certified doctors treat each client, and the treatment pages require a medical evaluation before a prescription; no individual prescriber is named.Source: Maximus' about page.

S2PASSA guest onboarding intake on the application subdomain comes before any payment field.Source: Maximus' weight loss start page on its app site.

S3FAILThe about page heads a section on selecting pharmacy partners and names none. The terms, privacy, contact and treatment surfaces add no facility.Source: Maximus' about page.

S4PASSThe semaglutide page states that compounded semaglutide is available by prescription only after medical evaluation and is not Food and Drug Administration approved.Source: Maximus' semaglutide standard page.

S5FAILNo certificate, lot number or purity figure appears on the site.Source: Maximus' weight loss page.

S6PASSThe terms and the privacy policy both print a street address with a unit number on Main Street in Santa Monica, California, given for written notice.Source: Maximus' terms of use page.

S7PASSThe homepage prints three starting figures with no account required, at 149.99 dollars, 199.99 dollars and 249.99 dollars, and the intake opens at 179 dollars per month.Source: Maximus' website.

S8PASSFDA warning letter 730095, June 2026, names Maximus Health, Inc. at the street address this site prints, and cites claims that a compounded product is clinically studied. No FDA action has halted the business, and the seller still trades.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Enforcement documents on file: 1 warning letter

FDA warning letter 730095, issued June 2026, to Maximus Health, Inc. dba MaximusClaims on Maximus' website that its compounded semaglutide and tirzepatide are clinically studied and proven to lose weight are false or misleading.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Visit Maximus

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.